Drug profile · INN
apremilast
OTEZLA
apremilast (OTEZLA) is a phosphodiesterase 4 inhibitor. Associated with Amgen. Route of administration: oral. Current US regulatory status: approved.
Drug details — apremilast
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 1
- Programs
- 8
- Data quality
- 0.89
Quick answer
apremilast (OTEZLA) is a phosphodiesterase 4 inhibitor. Associated with Amgen. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Phosphodiesterase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is apremilast?
apremilast (OTEZLA) is a phosphodiesterase 4 inhibitor. Associated with Amgen. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for apremilast?
OTEZLA is a marketed brand name for apremilast. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of apremilast?
apremilast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.